Advanced glycation end product 3 (AGE3) suppresses the mineralization of mouse stromal ST2 cells and human mesenchymal stem cells by increasing TGF-β expression and secretion

Endocrinology

Volumn 155, Issue 7, 2014, Pages 2402-2410

  Notsu, Masakazu ^a   Yamaguchi, Toru ^a   Okazaki, Kyoko ^a   Tanaka, Ken Ichiro ^a   Ogawa, Noriko ^a   Kanazawa, Ippei ^a   Sugimoto, Toshitsugu ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (5 CHLORO 2 FLUOROPHENYL) 4 (4 PYRIDINYLAMINO)PTERIDINE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT 3; OSTEOCALCIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; BONE MINERALIZATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STROMA CELL;

ANIMALS; APOPTOSIS; CALCIFICATION, PHYSIOLOGIC; CELL LINE; CELL PROLIFERATION; CORE BINDING FACTOR ALPHA 1 SUBUNIT; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MESENCHYMAL STROMAL CELLS; MICE; OSTEOCALCIN; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, IMMUNOLOGIC; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STROMAL CELLS; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84903289572     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1818     Document Type: Article

References (65)

1. Johnell O, Kanis JA, Odén A, et al. Mortality after osteoporotic fractures. Osteoporos Int. 2004;15(1):38-42. (Pubitemid 38252438)
2. Fox CS, Pencina MJ, Meigs JB, Vasan RS, Levitzky YS, D'Agostino RB Sr. Trends in the incidence of type 2 diabetes mellitus from the 1970s to the 1990s: the Framingham Heart Study. Circulation. 2006;113(25):2914-2918. (Pubitemid 44297232)
3. Yoshimura N, Muraki S, Oka H, Kawaguchi H, Nakamura K, Akune T. Cohort profile: research on Osteoarthritis/Osteoporosis Against Disability Study. Int J Epidemiol. 2010;39(4):988-995.
4. Orimo H, Yaegashi Y, Onoda T, Fukushima Y, Hosoi T, Sakata K. Hip fracture incidence in Japan: estimates of new patients in 2007 and 20-year trends. Arch Osteoporos. 2009;4(1-2):71-77.
5. Yoshimura N, Muraki S, Oka H, et al. Prevalence of knee osteoarthritis, lumbar spondylosis, and osteoporosis in Japanese men and women: the research on osteoarthritis/osteoporosis against disability study. J Bone Miner Metab. 2009;27(5):620-628.
6. Schwartz AV, Sellmeyer DE, Ensrud KE, et al. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab. 2001;86(1):32-38. (Pubitemid 32109771)
7. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes-a meta-analysis. Osteoporos Int. 2007;18(4):427-444. (Pubitemid 46354916)
8. Yamamoto M, Yamaguchi T, Yamauchi M, Kaji H, Sugimoto T. Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications. J Bone Miner Res. 2009;24(4):702-709.
9. Bouillon R, Bex M, Van Herck E, et al. Influence of age, sex, and insulin on osteoblast function: osteoblast dysfunction in diabetes mellitus. J Clin Endocrinol Metab. 1995;80(4):1194-1202.
10. Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Yano S, Sugimoto T. Serum osteocalcin/bone-specific alkaline phosphatase ratio is a predictor for the presence of vertebral fractures in men with type 2 diabetes. Calcif Tissue Int. 2009;85(3):228-234.
11. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia. 2001;44(2):129-146. (Pubitemid 32156196)
12. Pongor S, Ulrich PC, Bencsath FA, Cerami A. Aging of proteins: isolation and identification of a fluorescent chromophore from the reaction of polypeptides with glucose. Proc Natl Acad Sci USA. 1984;81(9):2684-2688. (Pubitemid 14109324)
13. Saito M, Fujii K, Mori Y, Marumo K. Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporos Int. 2006;17(10):1514-1523. (Pubitemid 44387486)
14. Yamamoto M, Yamaguchi T, Yamauchi M, Yano S, Sugimoto T. Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab. 2008;93(3):1013-1019. (Pubitemid 351398587)
15. Schwartz AV, Garnero P, Hillier TA, et al. Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab. 2009;94(7):2380-2386.
16. Yamamoto M, Yamaguchi T, Yamauchi M, Sugimoto T. Low serum level of the endogenous secretory receptor for advanced glycation end products (esRAGE) is a risk factor for prevalent vertebral fractures independent of bone mineral density in patients with type 2 diabetes. Diabetes Care. 2009;32(12):2263-2268.
17. Otsuka E, Yamaguchi A, Hirose S, Hagiwara H. Characterization of osteoblastic differentiation of stromal cell line ST2 that is induced by ascorbic acid. Am J Physiol. 1999;277(1 pt 1):C132-C138. (Pubitemid 29352633)
18. Yamaguchi A, Ishizuya T, Kintou N, et al. Effects of BMP-2, BMP-4, and BMP-6 on osteoblastic differentiation of bone marrow-derived stromal cell lines, ST2 and MC3T3-G2/PA6. Biochem Biophys Res Commun. 1996;220(2):366-371. (Pubitemid 26110126)
19. Okazaki K, Yamaguchi T, Tanaka K, et al. Advanced glycation end products (AGEs), but not high glucose, inhibit the osteoblastic differentiation of mouse stromal ST2 cells through the suppression of osterix expression, and inhibit cell growth and increasing cell apoptosis. Calcif Tissue Int. 2012;91(4):286-296.
20. Ogawa N, Yamaguchi T, Yano S, Yamauchi M, Yamamoto M, Sugimoto T. The combination of high glucose and advanced glycation end-products (AGEs) inhibits the mineralization of osteoblastic MC3T3-E1 cells through glucose-induced increase in the receptor for AGEs. Horm Metab Res. 2007;39(12):871-875.
21. Massagué J, Blain SW, Lo RS. TGFβ signaling in growth control, cancer, and heritable disorders. Cell. 2000;103(2):295-309.
22. Janssens K, ten Dijke P, Janssens S, Van Hul W. Transforming growth factor-β1 to the bone. Endocr Rev. 2005;26(6):743-774.
23. Alliston T, Choy L, Ducy P, Karsenty G, Derynck R. TGF-β-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. EMBO J. 2001;20(9):2254-2272. (Pubitemid 32410595)
24. Kang JS, Alliston T, Delston R, Derynck R. Repression of Runx2 function by TGF-β through recruitment of class II histone deacetylases by Smad3. EMBO J. 2005;24(14):2543-2555. (Pubitemid 41076311)
25. Balooch G, Balooch M, Nalla RK, et al. TGF-β regulates the mechanical properties and composition of bone matrix. Proc Natl Acad Sci USA. 2005;102(52):18813-18818. (Pubitemid 43049527)
26. Chang JL, Brauer DS, Johnson J, et al. Tissue-specific calibration of extracellular matrix material properties by transforming growth factor-β and Runx2 in bone is required for hearing. EMBO Rep. 2010;11(10):765-771.
27. Edwards JR, Nyman JS, Lwin ST, et al. Inhibition of TGF-β signaling by 1D11 antibody treatment increases bone mass and quality in vivo. J Bone Miner Res. 2010;25(11):2419-2426.
28. Mohammad KS, Chen CG, Balooch G, et al. Pharmacologic inhibition of the TGF-β type I receptor kinase has anabolic and anticatabolic effects on bone. PLoS One. 2009;4(4):e5275.
29. Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA. Expression of transforming growth factor β is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA. 1993;90(5):1814-1818. (Pubitemid 23069947)
30. Iwano M, Kubo A, Nishino T, Sato H, et al. Quantification of glomerular TGF-β 1 mRNA in patients with diabetes mellitus. Kidney Int. 1996;49(4):1120-1126. (Pubitemid 26122715)
31. Pankewycz OG, Guan JX, Bolton WK, Gomez A, Benedict JF. Renal TGF-β regulation in spontaneously diabetic NOD mice with correlations in mesangial cells. Kidney Int. 1994;46(3):748-758. (Pubitemid 24272033)
32. Sharma K, Jin Y, Guo J, Ziyadeh FN. Neutralization of TGF-β by anti-TGF-β antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes. 1996;45(4):522-530.
33. Throckmorton DC, Brogden AP, Min B, Rasmussen H, Kashgarian M. PDGF and TGF-β mediate collagen production by mesangial cells exposed to advanced glycosylation end products. Kidney Int. 1995;48(1):111-117.
34. Ziyadeh FN, Han DC, Cohen JA, Guo J, Cohen MP. Glycated albumin stimulates fibronectin gene expression in glomerular mesangial cells: involvement of the transforming growth factor-β system. Kidney Int. 1998;53(3):631-638. (Pubitemid 28124277)
35. Ybarra J, Pou JM, Romeo JH, Merce J, Jurado J. Transforming growth factor β 1 as a biomarker of diabetic peripheral neuropathy: cross-sectional study. J Diabetes Complications. 2010;24(5):306-312.
36. Shimizu F, Sano Y, Haruki H, Kanda T. Advanced glycation end-products induce basement membrane hypertrophy in endoneurial microvessels and disrupt the blood-nerve barrier by stimulating the release of TGF-β and vascular endothelial growth factor (VEGF) by pericytes. Diabetologia. 2011;54(6):1517-1526.
37. Pfeiffer A, Spranger J, Meyer-Schwickerath R, Schatz H. Growth factor alterations in advanced diabetic retinopathy: a possible role of blood retina barrier breakdown. Diabetes. 1997;46(suppl 2):S26-S30. (Pubitemid 27377394)
38. Matsumoto Y, Takahashi M, Ogata M. Relationship between glycoxidation and cytokines in the vitreous of eyes with diabetic retinopathy. Jpn J Ophthalmol. 2002;46(4):406-412. (Pubitemid 35286592)
39. Kanazawa I, Yamaguchi T, Yano S, Yamauchi M, Sugimoto T. Fasudil hydrochloride induces osteoblastic differentiation of stromal cell lines, C3H10T1/2 and ST2, via bone morphogenetic protein-2 expression. Endocr J. 2010;57(5):415-421.
40. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔC(T)) method. Methods. 2001;25(4):402-408. (Pubitemid 34164012)
41. Maeda S, Hayashi M, Komiya S, Imamura T, Miyazono K. Endogenous TGF-β signaling suppresses maturation of osteoblastic mesenchymal cells. EMBO J. 2004;23(3):552-563. (Pubitemid 38282387)
42. Takeuchi K, Abe M, Hiasa M, et al. TGF-β inhibition restores terminal osteoblast differentiation to suppress myeloma growth. PLoS One. 2010;5(3):e9870.
43. Komori T. Regulation of osteoblast differentiation by transcription factors. J Cell Biochem. 2006;99(5):1233-1239.
44. Tada Y, Yano S, Yamaguchi T, et al. Advanced glycation end products-induced vascular calcification is mediated by oxidative stress: functional roles of NAD(P)H-oxidase. Horm Metab Res. 2013;45(4):267-272.
45. Suzuki H, Kurihara Y, Takeya M, et al. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature. 1997;386(6622):292-296. (Pubitemid 27142516)
46. Araki N, Higashi T, Mori T, et al. Macrophage scavenger receptor mediates the endocytic uptake and degradation of advanced glycation end products of the Maillard reaction. Eur J Biochem. 1995;230(2):408-415.
47. Ramasamy R, Yan SF, Schmidt AM. Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Ann NY Acad Sci. 2011;1243:88-102.
48. Ohgami N, Nagai R, Ikemoto M, et al. Cd36, a member of the class b scavenger receptor family, as a receptor for advanced glycation end products. J Biol Chem. 2001;276(5):3195-3202.
49. Rudijanto A. The expression and down stream effect of lectin like-oxidized low density lipoprotein 1 (LOX-1) in hyperglycemic state. Acta Med Indones. 2007;39(1):36-43.
50. Lai KN, Leung JC, Chan LY, et al. Differential expression of receptors for advanced glycation end-products in peritoneal mesothelial cells exposed to glucose degradation products. Clin Exp Immunol. 2004;138(3):466-475. (Pubitemid 39573627)
51. Noda M, Camilliere JJ. In vivo stimulation of bone formation by transforming growth factor-β. Endocrinology. 1989;124(6):2991-2994. (Pubitemid 19154136)
52. Fujimoto R, Tanizawa T, Nishida S, et al. Local effects of transforming growth factor-β1 on rat calvaria: changes depending on the dose and the injection site. J Bone Miner Metab. 1999;17(1):11-17. (Pubitemid 29117746)
53. Bodine PV, Billiard J, Moran RA, et al. The Wnt antagonist secreted frizzled-related protein-1 controls osteoblast and osteocyte apoptosis. J Cell Biochem. 2005;96(6):1212-1230. (Pubitemid 41681864)
54. Chua CC, Chua BH, Chen Z, Landy C, Hamdy RC. TGF-β1 inhibits multiple caspases induced by TNF-α in murine osteoblastic MC3T3-E1 cells. Biochim Biophys Acta. 2002;1593(1):1-8. (Pubitemid 35335906)
55. Dufour C, Holy X, Marie PJ. Transforming growth factor-β prevents osteoblast apoptosis induced by skeletal unloading via PI3K/Akt, Bcl-2, and phospho-Bad signaling. Am J Physiol Endocrinol Metab. 2008;294(4):E794-E801. (Pubitemid 351483605)
56. Borton AJ, Frederick JP, Datto MB, Wang XF, Weinstein RS. The loss of Smad3 results in a lower rate of bone formation and osteopenia through dysregulation of osteoblast differentiation and apoptosis. J Bone Miner Res. 2001;16(10):1754-1764. (Pubitemid 32911480)
57. Harris SE, Bonewald LF, Harris MA, et al. Effects of transforming growth factor β on bone nodule formation and expression of bone morphogenetic protein 2, osteocalcin, osteopontin, alkaline phosphatase, and type I collagenmRNAin long-term cultures of fetal rat calvarial osteoblasts. J Bone Miner Res. 1994;9(6):855-863.
58. Edelstein SL, Barrett-Connor E. Relation between body size and bone mineral density in elderly men and women. Am J Epidemiol. 1993;138(3):160-169. (Pubitemid 23253933)
59. Hannan MT, Felson DT, Anderson JJ. Bone mineral density in elderly men and women: results from the Framingham osteoporosis study. J Bone Miner Res. 1992;7(5):547-553.
60. Nguyen TV, Sambrook PN, Eisman JA. Bone loss, physical activity, and weight change in elderly women: the Dubbo Osteoporosis Epidemiology Study. J Bone Miner Res. 1998;13(9):1458-1467. (Pubitemid 28418913)
61. Reid IR. Relationshipsamongbody mass, its components, and bone. Bone. 2002;31:547-555. (Pubitemid 35449695)
62. Abrahamsen B, Rohold A, Henriksen JE, Beck-Nielsen H. Correlations between insulin sensitivity and bone mineral density in nondiabetic men. Diabet Med. 2000;17:124-129. (Pubitemid 30159047)
63. Reid IR, Evans MC, Cooper GJ, Ames RW, Stapleton J. Circulating insulin levels are related to bone density in normal postmenopausal women. Am J Physiol. 1993;265:E655-E659.
64. Kanazawa I, Yamaguchi T, Yamauchi M, et al. Adiponectin is associated with changes in bone markers during glycemic control in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2009;94(8):3031-3037.
65. Okazaki R, Totsuka Y, Hamano K, et al. Metabolic improvement of poorly controlled noninsulin-dependent diabetes mellitus decreases bone turnover. J Clin Endocrinol Metab. 1997;82(9):2915-2920. (Pubitemid 27385648)